SUBSCRIBERS
J&J to buy Actelion for US$30b and spin off Swiss drugmaker's R&D unit
World's largest maker of healthcare products pips Sanofi of France to the deal despite walking away earlier
Add BT as a preferred sourcePublished Thu, Jan 26, 2017 · 09:50 PM
DeeperDive is a beta AI feature. Refer to full articles for the facts.
New York
JOHNSON & JOHNSON agreed to buy Actelion Ltd for US$30 billion and spin off the Swiss drugmaker's research and development operations, clinching its largest deal ever to become a leader in medicines treating a rare type of high blood pressure.
With the purchase, J&J, already the world's biggest maker of healthcare products, is fulfilling its goal of adding a new drug category and dealing a blow to France's Sanofi, which had also sought to acquire Actelion.
Share with us your feedback on BT's products and services
